Perspectum and ProPath have collaborated to enable pharmaceutical companies running clinical trials for liver disease to receive pathology and imaging expertise from one contract research organisation (CRO).
Under the collaboration, pharmaceutical companies will be able to access new imaging technologies and a pathology service for continuous monitoring, enabling better-informed decision making.
Clinical trials using the expertise of this partnership will benefit from streamlined clinical data management through a single cloud-based platform.
Imaging data provided by both companies will facilitate reliable trial enrolment, accelerating clinical study timelines.
Perspectum US Operations head Dr Cathy O’Hare said: “We are excited to start this partnership with ProPath, which will enable us to expand Perspectum’s efforts to streamline and improve decision-making in liver disease clinical trials.
“This combined offering will provide our customers with access to best-in-class pathology and imaging in an integrated workflow.
“This collaboration also builds on Perspectum’s work developing digital pathology solutions, and we look forward to seeing these developments improve the landscape of clinical trials in liver, metabolic disease, and beyond.”
The two entities will work on providing a digital pathology solution, which not only offers reports from digitised biopsy images but also provides storage for these images.
ProPath president, chairman and CEO Cory Roberts said: “Together, we can provide a single, best quality location for contract research services. This will make it easy for investigators and companies to get all of their needs met and expectations exceeded in one place, faster and better than ever before.”
